Pulmonx (NASDAQ:LUNG) Given Buy Rating at D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a "Buy" rating for Pulmonx, maintaining a price target of $16.00 despite varying opinions from other analysts.
• Multiple analysts have recently lowered their price targets for Pulmonx, with estimates ranging significantly, indicating uncertainty in the stock's prospects.
• Pulmonx reported a quarterly EPS of ($0.38), which surpassed expectations, alongside a revenue of $23.86 million, indicating potential resilience in performance.

Pulmonx (NASDAQ:LUNG - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $16.00 price target on the stock.

Other research analysts also recently issued research reports about the stock. Wells Fargo & Company dropped their price objective on shares of Pulmonx from $6.00 to $3.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Wall Street Zen raised shares of Pulmonx from a "sell" rating to a "hold" rating in a research note on Saturday, August 30th. Citigroup dropped their price objective on shares of Pulmonx from $6.50 to $4.15 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Piper Sandler downgraded shares of Pulmonx from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $9.00 to $2.50 in a research note on Thursday, July 31st. Finally, Lake Street Capital dropped their price objective on shares of Pulmonx from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday, July 31st. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Pulmonx currently has a consensus rating of "Moderate Buy" and an average price target of $7.66.

Pulmonx Trading Up 0.6%

NASDAQ:LUNG traded up $0.01 on Monday, reaching $1.70. The stock had a trading volume of 248,472 shares, compared to its average volume of 562,197. The company has a market cap of $69.27 million, a price-to-earnings ratio of -1.19 and a beta of 0.43. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.35 and a quick ratio of 4.63. The firm's fifty day moving average is $2.14 and its two-hundred day moving average is $3.91. Pulmonx has a 12-month low of $1.47 and a 12-month high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. The company had revenue of $23.86 million for the quarter, compared to analyst estimates of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. Pulmonx has set its FY 2025 guidance at EPS. Equities analysts expect that Pulmonx will post -1.55 EPS for the current fiscal year.

Institutional Trading of Pulmonx

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers increased its position in Pulmonx by 4.6% during the 1st quarter. Rhumbline Advisers now owns 55,958 shares of the company's stock worth $377,000 after purchasing an additional 2,455 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Pulmonx by 1.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 320,946 shares of the company's stock worth $2,160,000 after purchasing an additional 5,414 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Pulmonx during the 4th quarter worth approximately $43,000. Graham Capital Management L.P. increased its position in Pulmonx by 73.3% during the 4th quarter. Graham Capital Management L.P. now owns 18,071 shares of the company's stock worth $123,000 after purchasing an additional 7,641 shares in the last quarter. Finally, Northern Trust Corp increased its position in Pulmonx by 2.9% during the 4th quarter. Northern Trust Corp now owns 372,659 shares of the company's stock worth $2,530,000 after purchasing an additional 10,433 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.